Bicara Therapeutics Inc
(BCAX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -29,557 | -12,508 | -51,985 | -39,545 |
| Depreciation Amortization | 26 | 13 | 19 | 5 |
| Other Working Capital | -280 | -3,304 | -9,624 | -12,568 |
| Other Operating Activity | 2,316 | 1,212 | 15,962 | 14,516 |
| Operating Cash Flow | $-27,495 | $-14,587 | $-45,628 | $-37,592 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | 39 | 58 | -586 | -150 |
| Investing Cash Flow | $39 | $58 | $-586 | $-150 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 1,467 | 137 | N/A | 149 |
| Other Financing Activity | -596 | 0 | 272,496 | 77,645 |
| Financing Cash Flow | $871 | $137 | $272,496 | $77,794 |
| Beginning Cash Position | 230,440 | 230,440 | 4,158 | 4,158 |
| End Cash Position | 203,855 | 216,048 | 230,440 | 44,210 |
| Net Cash Flow | $-26,585 | $-14,392 | $226,282 | $40,052 |
| Free Cash Flow | ||||
| Operating Cash Flow | -27,495 | -14,587 | -45,628 | -37,592 |
| Capital Expenditure | -23 | -4 | N/A | -150 |
| Free Cash Flow | -27,518 | -14,591 | -45,628 | -37,742 |